 Regeneron Pharmaceuticals Inc. REGN, 3.91 said Thursday that an 8-milligram dose of aflibercept successfully treated patients with diabetic macular edema and wet age-related macular degeneration in a pair of pivotal trials. Regenerons stock was halted ahead of the announcement. 